Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

23 June 2014 : Original article  

Incidence of malignant neoplasia after heart transplantation – a comparison between cyclosporine a and tacrolimus

Uwe FuchsABD, Sarah KleinBCD, Armin ZittermannBCDE, Stephan M. EnsmingerDE, Uwe SchulzADF, Jan F. GummertBD

DOI: 10.12659/AOT.890199

Ann Transplant 2014; 19:300-304

Abstract

BACKGROUND: Heart transplant recipients are at increased risk of developing malignant neoplasms. Administration of the calcineurin inhibitors cyclosporine A (CSA) or tacrolimus (TAC) may contribute to this risk.

MATERIAL AND METHODS: We compared tumor incidence in heart transplant recipients receiving either CSA (n=25) or TAC (n=120) as maintenance immunosuppressive therapy. Exclusion criteria were therapy with mammalian target of rapamycin-inhibitors, death within the first postoperative year, re-transplantation, and age less than 18 years.

RESULTS: The 2 study groups were comparable with respect to sex, primary and concomitant diagnoses, and mean follow-up (60.7±19.3 months in the CSA group vs. 59.8±18.1 months in the TAC group; P=0.81). The CSA group was, however, significantly older compared with the TAC group (58.8±11.4 years vs. 49.1±13.0 years, P=0.001), as was the donor age of the CSA group (43.2±11.2 years vs. 37.0±11.7 years, P=0.02). In the CSA group, 5 patients (20%) developed malignant neoplasms compared with 10 patients (8.3%) in the TAC group (P=0.14). Covariate-adjusted 5-year tumor-free survival was comparable between groups (relative risk for the CSA group =1.162 [95% CI: 0.378–3.572; P=0.794]). Moreover, covariate-adjusted 5-year overall survival did not differ between the 2 groups (relative risk for the CSA group =1.95 [95% CI: 0.53–7.19; P=0.36). The incidence of infection, acute rejection, graft vasculopathy, renal failure, and neurological complications was also comparable between the 2 groups.

CONCLUSIONS: Our data indicate that tumor incidence does not significantly differ in patients receiving CSA or TAC as maintenance therapy.

Keywords: Neoplasms, Second Primary, Tacrolimus, Cyclosporine A, Immunosuppression, calcineurin-inhibitors, Heart Transplantation

Add Comment 0 Comments

839 12

In Press

14 Sep 2023 : Case report  

Intrahepatic Venous Collateral Circulation and Reverse Blood Flow After Main Hepatic Vein Obstruction: A Ca...

Ann Transplant In Press; DOI: 10.12659/AOT.941521  

12 Sep 2023 : Original article  

Three-Dimensional Printing of Polycaprolactone/Nano-Hydroxyapatite Composite Scaffolds with a Pore Size of ...

Ann Transplant In Press; DOI: 10.12659/AOT.940365  

04 Sep 2023 : Original article  

Analysis of Anxiety and Influencing Factors in Kidney Transplant Recipients and General Public During the C...

Ann Transplant In Press; DOI: 10.12659/AOT.941489  

04 Sep 2023 : Original article  

Prolonged Tracheal Intubation in the ICU as a Possible Risk Factor for Arytenoid Dislocation After Liver Tr...

Ann Transplant In Press; DOI: 10.12659/AOT.940727  

Most Viewed Current Articles

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358